niacin and ezetimibe

niacin has been researched along with ezetimibe in 107 studies

Research

Studies (107)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	42 (39.25)	29.6817
2010's	60 (56.07)	24.3611
2020's	5 (4.67)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bruckert, E	1
Ballantyne, CM; Xydakis, AM	1
Brown, AS	1
Davidson, MH	1
Cottrell, DA; Falko, JM; Marshall, BJ	1
Davidson, MH; Toth, PP	1
Denke, MA	1
Charlotte, N; Sani, M	1
Ansell, BJ	2
Mosca, L	1
McKenney, JM	1
Ducobu, J	1
Balbisi, EA	1
Schulz, I	1
Patel, J	1
Cicero, AF; Derosa, G; Salvadeo, S	1
Backes, JM; Gibson, CA; Howard, PA	1
Balcerak, M; Broncel, M; Chojnowska-Jezierska, J	1
Bhardwaj, SS; Chalasani, N	1
Bouknight, P; Heffington, M; Mackler, L	1
Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A	1
Brown, BG; Fazio, S; Guyton, JR; Polis, A; Tershakovec, AM; Tomassini, JE	1
Kaye, T	1
Robinson, JG	1
Guthrie, R	1
Hughes, S	1
Bulai Livideanu, C; Ferrières, J; Lamant, L; Maybon, P; Mazereeuw-Hautier, J; Paul, C; Periquet, B; Royer, M	1
Goldberg, AC; Hou, R	1
Avis, HJ; Hutten, BA; Kastelein, JJ; Vissers, MN; Wijburg, FA	1
Jones, PH	1
Blumenthal, RS; Michos, ED	1
Devine, PJ; Griffen, L; Miller, M; Stanek, EJ; Taylor, AJ; Turco, M; Villines, TC; Weissman, NJ	2
Bots, ML; Kastelein, JJ	1
Charland, SL; Malone, DC	1
Kole, LA	1
Parhofer, K	1
Mitka, M	1
Rosenson, RS	1
Adewale, AJ; Fazio, S; Guyton, JR; Polis, AB; Ryan, NW; Tershakovec, AM; Tomassini, JE	1
Dunn, FL	1
Halcox, JP; Lindsay, AC	1
Duivenvoorden, R; Kastelein, JJ; Vergeer, M	1
Roman, MJ	1
Weiss, SH	1
Ferrario, CM	1
Ahmed, MH	1
Phillips, W; Schaefer, S	1
Rizzoni, D; Rossi, GP	1
Drakopoulou, M; Skoumas, I; Stefanadis, C; Toutouzas, K	1
Gupta, A; Guyomard, V; Myint, PK; Rehman, HU; Zaman, MJ	1
Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS	1
Olsson, AG	1
Lee, T	1
Jacobson, TA	1
Cutler, DL; Kim, KT; Kosoglou, T; Statkevich, P; Taggart, W; Triantafyllou, I; Xuan, F; Zhu, Y	1
Ballantyne, CM; Dong, JF; Kimball, KT; Lumsden, AB; Morrisett, JD; Nambi, V; Saunders, J; Virani, SS	1
Doggrell, SA	1
Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA	1
Elis, A; Stein, EA; Zhou, R	1
Sharma, M	1
Diep, F	1
Bandgar, TR; Faruqui, AA	1
Prasad, V; Vandross, A	1
Banach, M; Davidson, M; Mikhailidis, DP; Nicholls, SJ; Otocka-Kmiecik, A; Rysz, J	1
Critchley, WR; Shah, MK; Shaw, SM; Williams, SG; Yonan, N	1
Cabré, A; Masana, L; Plana, N	1
Abate, N; Montalto, G; Nikolic, D; Rizvi, AA; Rizzo, M; Sallam, HS	1
Ballantyne, CM; Brunner, G; Chen, C; Dong, JF; Hoogeveen, RC; Kougias, P; Kumar, A; Lin, PH; Lumsden, AB; Morrisett, JD; Murray, T; Nambi, V; Negi, SI; Sun, W; Taylor, A; Virani, SS; Yang, EY	1
Bajnok, L	1
Chelladurai, Y; Gudzune, KA; Monroe, AK; Ranasinghe, PD; Robinson, KA; Sharma, R	1
Jain, M; Zafrir, B	1
Brudi, P; Catapano, AL; Farnier, M; Foody, JM; Tershakovec, AM; Tomassini, JE; Toth, PP	1
Güleç, S; Özcan, ÖU	1
Sekhar, RV	1
Kramer, W	1
Knight, M; Sando, KR	1
Bittner, V; Deng, L; Farkouh, ME; Glasser, SP; Kent, ST; Muntner, P; Rosenson, RS; Taylor, B	1
Albers, JJ; Fleg, JL; Marcovina, SM; O'Brien, KD; Slee, A	1
Collins, PD; Sattar, N	1
Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S	1
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N	1
Nozue, T	1
Agrawal, S; Fornoni, A; Smoyer, WE; Zaritsky, JJ	1
Athyros, VG; Giannoukas, AD; Katsiki, N; Mikhailidis, DP	1
Hsiung, JT; Kleine, CE; Moradi, H; Park, C; Soohoo, M; Streja, DA; Streja, E	1
Fichtenbaum, CJ; Gebhardt, A	1
Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS	1
Chen, Q; Guo, Q; He, Z; Li, H; Lu, L; Sun, R; Wang, J; Xu, X; Zhang, Y	1
Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C	1
Huang, T; Jiao, L; Li, L; Luo, J; Ma, Y; Wang, J; Wang, T; Wang, X; Xu, R; Yang, B; Yang, H; Yang, R; Yang, Y; Zhang, X; Zhang, Y	1
Allan, GM; Braschi, É; Dugré, N; Falk, J; Froentjes, L; Garrison, SR; Kirkwood, JEM; Kolber, MR; Korownyk, CS; Lindblad, AJ; McCormack, JP; Moe, SS; Paige, A; Perry, D; Potter, J; Thomas, BS; Ton, J; Weresch, J; Young, J	1

Reviews

51 review(s) available for niacin and ezetimibe

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology, 2002, Volume: 97, Issue:2 Topics: Acetamides; Acetates; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Sulfonic Acids	2002
Combination therapy for combined dyslipidemia. The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Niacin; Practice Guidelines as Topic; Triglycerides	2002
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Current opinion in cardiology, 2003, Volume: 18, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fenofibrate; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Particle Size	2003
Combination therapy in the management of complex dyslipidemias. Current opinion in lipidology, 2004, Volume: 15, Issue:4 Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Niacin	2004
Coadministration of multidrug therapy to achieve lipid goals. The Journal of the American Osteopathic Association, 2004, Volume: 104, Issue:9 Suppl 7 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Risk Factors	2004
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Current atherosclerosis reports, 2005, Volume: 7, Issue:1 Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Niacin; Quinolines	2005
Drugs for lipids. Treatment guidelines from the Medical Letter, 2005, Volume: 3, Issue:31 Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Bile Acids and Salts; Cholesterol; Cholesterol, LDL; Clofibric Acid; Drug Interactions; Ezetimibe; Female; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pregnancy; Triglycerides	2005
Management of dyslipidemia in women in the post-hormone therapy era. Journal of general internal medicine, 2005, Volume: 20, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dietary Supplements; Disease Management; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Niacin; Practice Guidelines as Topic; Triglycerides	2005
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. The American journal of cardiology, 2005, Aug-22, Volume: 96, Issue:4A Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2005
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. Medical science monitor : international medical journal of experimental and clinical research, 2006, Volume: 12, Issue:2 Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Style; Niacin; Risk Factors	2006
[Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Niacin	2006
Dyslipidaemia in diabetes. Clinical evidence, 2006, Issue:15 Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin	2006
Prospects for the development of novel anti-hyperlipidemic drugs. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:9 Topics: Animals; Azetidines; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Ezetimibe; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Microsomes; Niacin; Sterol O-Acyltransferase	2006
Optimal lipid modification: the rationale for combination therapy. Vascular health and risk management, 2005, Volume: 1, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Patient Compliance; Patient Selection; Practice Guidelines as Topic; Research Design; Treatment Outcome	2005
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2007, Volume: 22, Issue:127 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Risk Factors; Simvastatin	2007
Lipid-lowering agents that cause drug-induced hepatotoxicity. Clinics in liver disease, 2007, Volume: 11, Issue:3 Topics: Azetidines; Chemical and Drug Induced Liver Injury; Cholesterol Ester Transfer Proteins; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin	2007
FPIN's clinical inquiries. Best alternatives to statins for treating hyperlipidemia. American family physician, 2007, Oct-01, Volume: 76, Issue:7 Topics: Anion Exchange Resins; Azetidines; Clofibric Acid; Evidence-Based Medicine; Ezetimibe; Fatty Acids, Omega-3; Garlic; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Phytotherapy; Plant Preparations	2007
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vascular health and risk management, 2007, Volume: 3, Issue:4 Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2007
LDL reduction: how low should we go and is it safe? Current cardiology reports, 2008, Volume: 10, Issue:6 Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Muscular Diseases; Niacin; Risk Factors; Stroke	2008
A review of trials evaluating nonstatin lipid-lowering therapies. Current atherosclerosis reports, 2009, Volume: 11, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Niacin	2009
Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinology and metabolism clinics of North America, 2009, Volume: 38, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Niacin	2009
The use of lipid-lowering drug therapy in children and adolescents. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:3 Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Clofibric Acid; Disease Progression; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ion Exchange Resins; Niacin; Practice Guidelines as Topic; Treatment Outcome	2009
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current medical research and opinion, 2010, Volume: 26, Issue:2 Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin	2010
Management of dyslipidemia in people with type 2 diabetes mellitus. Reviews in endocrine & metabolic disorders, 2010, Volume: 11, Issue:1 Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides	2010
Advancing therapy for hypercholesterolemia. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10 Topics: Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Niacin	2010
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Advances in therapy, 2010, Volume: 27, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Evidence-Based Practice; Ezetimibe; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Patient Selection; Phytosterols; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Treatment Outcome	2010
'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. International journal of clinical practice, 2011, Volume: 65, Issue:1 Topics: Adult; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Practice Guidelines as Topic; Risk Factors; Young Adult	2011
Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011? Complementary therapies in medicine, 2011, Volume: 19, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Margarine; Micronutrients; Niacin; Phytosterols; Sitosterols; Triglycerides	2011
Combination therapy for dyslipidemia. Current opinion in cardiology, 2011, Volume: 26, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Niacin	2011
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Progress in lipid research, 2012, Volume: 51, Issue:4 Topics: Animals; Apolipoproteins; Azetidines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Peroxidase; Thiazolidinediones	2012
Second line options for hyperlipidemia management after cardiac transplantation. Cardiovascular therapeutics, 2013, Volume: 31, Issue:3 Topics: Azetidines; Bezafibrate; Diet; Exercise; Ezetimibe; Fish Oils; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin	2013
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents. Metabolic syndrome and related disorders, 2014, Volume: 12, Issue:1 Topics: Adipokines; Adipose Tissue; Animals; Anti-Obesity Agents; Azetidines; Ezetimibe; Fibric Acids; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Incretins; Insulin; Insulin Resistance; Lipids; Lipoproteins; Metabolic Syndrome; Metformin; Niacin; Thiazolidinediones	2014
[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Orvosi hetilap, 2014, Jan-12, Volume: 155, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Fibric Acids; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2014
Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Annals of internal medicine, 2014, Apr-01, Volume: 160, Issue:7 Topics: Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Omega-3; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Medication Adherence; Niacin; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome	2014
Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:4 Topics: Animals; Azetidines; Bile Acids and Salts; Blood Glucose; Cholesterol Ester Transfer Proteins; Diabetes Mellitus; Ezetimibe; Fibric Acids; Fish Oils; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Niacin	2014
Combination therapy in dyslipidemia: where are we now? Atherosclerosis, 2014, Volume: 237, Issue:1 Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Niacin; Patient Compliance; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome	2014
[Heterozygous familial hypercholesterolemia]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2014, Volume: 42 Suppl 2 Topics: Azetidines; Early Diagnosis; Ezetimibe; Genetic Predisposition to Disease; Genetic Testing; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Niacin	2014
Treatment of dyslipidemia in HIV. Current atherosclerosis reports, 2015, Volume: 17, Issue:4 Topics: Anti-HIV Agents; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diet Therapy; Dyslipidemias; Exercise Therapy; Ezetimibe; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fibric Acids; Glutathione; Growth Hormone-Releasing Hormone; HIV Infections; Human Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Niacin; Pyrazines; Thiazolidinediones; Triglycerides	2015
Antilipidemic Drug Therapy Today and in the Future. Handbook of experimental pharmacology, 2016, Volume: 233 Topics: Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Triglycerides	2016
Nonstatin therapies for management of dyslipidemia: a review. Clinical therapeutics, 2015, Oct-01, Volume: 37, Issue:10 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clofibrate; Disease Management; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Proprotein Convertases; Risk Factors; Saccharomyces cerevisiae Proteins; Triglycerides; United States	2015
Glycaemic Effects of Non-statin Lipid-Lowering Therapies. Current cardiology reports, 2016, Volume: 18, Issue:12 Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Meta-Analysis as Topic; Niacin; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome	2016
Lipid Lowering Therapy and Circulating PCSK9 Concentration. Journal of atherosclerosis and thrombosis, 2017, Sep-01, Volume: 24, Issue:9 Topics: Antibodies, Monoclonal; Biomarkers; Cholesterol, LDL; Ezetimibe; Fibric Acids; Gene Silencing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Niacin; PCSK9 Inhibitors; Proprotein Convertase 9	2017
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nature reviews. Nephrology, 2018, Volume: 14, Issue:1 Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins; Nephrotic Syndrome; Niacin; Proprotein Convertase 9; Triglycerides	2018
Lipid-lowering treatment in peripheral artery disease. Current opinion in pharmacology, 2018, Volume: 39 Topics: Animals; Cholesterol Ester Transfer Proteins; Ezetimibe; Fibric Acids; Humans; Hypolipidemic Agents; Niacin; PCSK9 Inhibitors; Peripheral Arterial Disease	2018
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease. Seminars in nephrology, 2018, Volume: 38, Issue:4 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Failure, Chronic; Muscular Diseases; Niacin; PCSK9 Inhibitors; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Renal Dialysis; Renal Insufficiency, Chronic	2018
Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:14 Topics: Anti-Retroviral Agents; Drug Interactions; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Risk Assessment	2019
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3 Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Patient Acuity; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors	2021
The comparative impact among different intensive statins and combination therapies with niacin/ezetimibe on carotid intima-media thickness: a systematic review, traditional meta-analysis, and network meta-analysis of randomized controlled trials. European journal of clinical pharmacology, 2021, Volume: 77, Issue:8 Topics: Carotid Intima-Media Thickness; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Network Meta-Analysis; Niacin; Randomized Controlled Trials as Topic	2021
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. Current problems in cardiology, 2023, Volume: 48, Issue:8 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; Proprotein Convertases; Secondary Prevention; Subtilisins	2023
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews. Canadian family physician Medecin de famille canadien, 2023, Volume: 69, Issue:10 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; PCSK9 Inhibitors; Primary Health Care; Proprotein Convertase 9; Systematic Reviews as Topic	2023

Trials

11 trial(s) available for niacin and ezetimibe

Article	Year
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology, 2008, Apr-22, Volume: 51, Issue:16 Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Simvastatin	2008
Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Niacin; Risk Factors; Single-Blind Method; Triglycerides; Tunica Intima; Tunica Media; Ultrasonography	2009
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. The American journal of cardiology, 2010, Feb-15, Volume: 105, Issue:4 Topics: Adolescent; Adult; Aged; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Niacin; Severity of Illness Index; Simvastatin; Tennessee; Time Factors; Treatment Outcome; Vitamin B Complex	2010
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. Journal of the American College of Cardiology, 2010, Jun-15, Volume: 55, Issue:24 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Niacin; Single-Blind Method; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography	2010
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. European journal of clinical pharmacology, 2011, Volume: 67, Issue:5 Topics: Adult; Anticholesteremic Agents; Azetidines; Cross-Over Studies; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Male; Niacin; Nicotinic Acids; Simvastatin; Tablets	2011
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. Journal of vascular surgery, 2011, Volume: 53, Issue:3 Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arachidonic Acid; Aspirin; Azetidines; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lower Extremity; Male; Middle Aged; Niacin; Peripheral Arterial Disease; Placebo Effect; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Stents; Time Factors; Treatment Outcome	2011
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothro American heart journal, 2011, Volume: 161, Issue:3 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Research Design; Simvastatin; Treatment Outcome	2011
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study partici American heart journal, 2011, Volume: 161, Issue:3 Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Triglycerides	2011
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis, 2013, Volume: 231, Issue:2 Topics: Aged; Azetidines; Cholesterol; Double-Blind Method; Endothelium, Vascular; Ezetimibe; Female; Femoral Artery; Humans; Lipids; Lipoproteins; Magnetic Resonance Imaging; Male; Middle Aged; Niacin; Peripheral Arterial Disease; Simvastatin	2013
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Atherosclerosis, 2016, Volume: 251 Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Niacin; Proportional Hazards Models; Simvastatin; Treatment Outcome; Triglycerides	2016
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3 Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Niacin; Oxazolidinones; Treatment Outcome	2017

Other Studies

45 other study(ies) available for niacin and ezetimibe

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Use of combination therapy for dyslipidemia: a lipid clinic approach. The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Triglycerides	2002
Combination therapy for dyslipidemia: safety and regulatory considerations. The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Safety	2002
Three new drugs for hyperlipidemia. The Medical letter on drugs and therapeutics, 2003, Mar-03, Volume: 45, Issue:1151 Topics: Azetidines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Intestinal Absorption; Lovastatin; Muscular Diseases; Niacin	2003
Three new drugs for hyperlipidemia. Connecticut medicine, 2003, Volume: 67, Issue:5 Topics: Azetidines; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin	2003
How doubling up drugs saves lives. Why doctors increasingly deploy an array of medications all at once. Heart advisor, 2004, Volume: 7, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Gemfibrozil; Humans; Niacin	2004
Lipid-lowering drugs. Nursing older people, 2004, Volume: 16, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Risk Factors; Treatment Outcome	2004
[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)]. Revue medicale de Bruxelles, 2005, Volume: 26, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Acids, Omega-3; Humans; Hyperlipidemias; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Piperidines; Pyrazoles; Rimonabant	2005
Lower cholesterol without statins. Options are available. Mayo Clinic health letter (English ed.), 2006, Volume: 24, Issue:5 Topics: Allylamine; Azetidines; Cholesterol, LDL; Cholinergic Antagonists; Colesevelam Hydrochloride; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Phytosterols	2006
Help for your cholesterol when statins won't do. If you are one of the many, but also one of the few... Harvard men's health watch, 2005, Volume: 9, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Male; Niacin	2005
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Niacin; Simvastatin	2008
Should we treat all primary prevention patients with statins? Current atherosclerosis reports, 2009, Volume: 11, Issue:1 Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Primary Prevention; Triglycerides; Vitamin B Complex	2009
On the road to better dyslipidemia outcomes. The Nurse practitioner, 2009, Volume: 34, Issue:2 Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Lipid Metabolism; Metabolic Syndrome; Niacin; Physical Examination; Risk Assessment; Risk Factors; Vitamin B Complex	2009
[Orange skin and xanthomas associated with lycopenaemia in a setting of type III dyslipoproteinemia]. Annales de dermatologie et de venereologie, 2009, Volume: 136, Issue:1 Topics: Azetidines; Carotenoids; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lycopene; Middle Aged; Niacin; Pigmentation Disorders; Skin Diseases; Xanthomatosis	2009
Achieving cholesterol goals. Current and future drug therapies. Postgraduate medicine, 2003, Volume: 114, Issue:2 Suppl Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin	2003
The HALTS trial--halting atherosclerosis or halted too early? The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Research Design; Tunica Intima; Tunica Media	2009
Statin therapy with ezetimibe or niacin in high-risk patients. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Research Design; Tunica Intima; Tunica Media	2009
Lipid disorders. JAAPA : official journal of the American Academy of Physician Assistants, 2009, Volume: 22, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Vitamin B Complex	2009
[Statin plus niacin or ezetimibe? What combination for which patients?]. MMW Fortschritte der Medizin, 2009, Dec-03, Volume: 151, Issue:49-50 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hypolipidemic Agents; Niacin; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Time Factors	2009
Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit. JAMA, 2010, Jan-20, Volume: 303, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Clinical Trials as Topic; Drug Approval; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin; Practice Patterns, Physicians'; Risk Factors; Simvastatin; Treatment Outcome; Ultrasonography; United States; United States Food and Drug Administration	2010
Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:1 Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Ezetimibe; Glucose; Humans; Insulin; Lipase; Lipoproteins, HDL; Niacin; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Blood Pressure; Carotid Arteries; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Vasodilator Agents	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Tunica Intima; Tunica Media	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Tunica Intima; Tunica Media	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Blood Glucose; Carotid Arteries; Coronary Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Humans; Niacin; Patient Dropouts; Research Design	2010
I have had trouble controlling my cholesterol with a statin alone. Should I consider prescription niacin? The Johns Hopkins medical letter health after 50, 2010, Volume: 21, Issue:12 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Niacin	2010
ARBITER 6-HALTS. Does it have the power to settle all matters? Therapeutic advances in cardiovascular disease, 2010, Volume: 4, Issue:2 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Niacin; Randomized Controlled Trials as Topic; Risk Factors	2010
Ezetimibe and recent clinical trials: a look on the bright side. Expert opinion on drug safety, 2010, Volume: 9, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Niacin; Placebos; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides	2010
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol. Preventive cardiology, 2010,Spring, Volume: 13, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Middle Aged; Niacin	2010
Therapy: raising HDL cholesterol levels: a flight of Icarus? Nature reviews. Endocrinology, 2010, Volume: 6, Issue:5 Topics: Atherosclerosis; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Niacin; Quinolines	2010
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. Preventive cardiology, 2010,Summer, Volume: 13, Issue:3 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex	2010
HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2010, Volume: 20, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Niacin	2010
Ask the doctor. I have tried all of the statin drugs to lower my cholesterol, but each one has caused severe muscle pain. Are there any non-statin medications I could try using to lower my cholesterol? Harvard heart letter : from Harvard Medical School, 2010, Volume: 20, Issue:12 Topics: Allylamine; Azetidines; Colesevelam Hydrochloride; Diet, Mediterranean; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Pain; Sitosterols	2010
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Current medical research and opinion, 2011, Volume: 27, Issue:5 Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors	2011
Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. The American journal of cardiology, 2011, Jul-15, Volume: 108, Issue:2 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Myocardial Revascularization; Niacin; Ohio; Pyrimidines; Registries; Rosuvastatin Calcium; Sulfonamides; Vitamin B Complex; Young Adult	2011
Trial clouds use of niacin with a statin. Harvard heart letter : from Harvard Medical School, 2011, Volume: 21, Issue:12 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Simvastatin; Treatment Failure	2011
Cholesterol conundrum. Scientific American, 2011, Volume: 305, Issue:5 Topics: Azetidines; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Risk Factors; Stroke	2011
Managing dyslipidaemia: evolving role of combination therapy. Journal of the Indian Medical Association, 2011, Volume: 109, Issue:8 Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles	2011
Cardiovascular primary prevention: how high should we set the bar? Archives of internal medicine, 2012, Apr-23, Volume: 172, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin	2012
HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe? Atherosclerosis, 2013, Volume: 229, Issue:2 Topics: Adaptor Protein Complex 3; Adaptor Protein Complex beta Subunits; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Hypolipidemic Agents; Indoles; Niacin; Simvastatin	2013
Drugs for lipids. Treatment guidelines from the Medical Letter, 2014, Volume: 12, Issue:137 Topics: Animals; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin	2014
Beyond statins: assessing the alternatives. Some people can't tolerate statins, and others need additional medications to achieve healthy cholesterol levels. Harvard heart letter : from Harvard Medical School, 2014, Volume: 25, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Bezafibrate; Cholesterol; Dietary Supplements; Exercise; Ezetimibe; Health Behavior; Health Promotion; Humans; Hyperlipidemias; Niacin	2014
Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011. Journal of the American College of Cardiology, 2015, Oct-27, Volume: 66, Issue:17 Topics: Adult; Anticholesteremic Agents; Coronary Disease; Drug Utilization; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Medicare; Niacin; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; United States	2015
Reducing CV risk in diabetes: An ADA update. The Journal of family practice, 2017, Volume: 66, Issue:5 Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones	2017
Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ open, 2022, 09-08, Volume: 12, Issue:9 Topics: Adult; Bile Acids and Salts; Ezetimibe; Fatty Acids; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Niacin; Proprotein Convertase 9; Proprotein Convertases; Review Literature as Topic; Subtilisin; Systematic Reviews as Topic	2022

chemdatabank.com